Cognitive Decline
Conditions
Keywords
Cognition
Brief summary
The purpose of this study is to see if a drug called lidocaine prevents cognitive injury (a decline in mental abilities) after heart surgery. Lidocaine is currently FDA approved and is commonly used for treating some heart rhythm disorders and for regional anesthesia (blocking nerves). The investigators are enrolling subjects in this research project to see if lidocaine will reduce the high incidence of cognitive injury seen after heart surgery. As part of this study, the investigators will also evaluate the relationship between cognitive injury and genetic makeup and the chemical changes in the subjects blood during and after surgery.
Interventions
Lidocaine versus placebo infusion for 48 hours
Lidocaine versus placebo infusion for 48 hours
Sponsors
Study design
Eligibility
Inclusion criteria
1. CABG, CABG + Valve, or Valve surgery 2. Use of cardiopulmonary bypass
Exclusion criteria
1. Less than 50 years of age 2. History of diabetes 3. History of symptomatic cerebrovascular disease (e.g. prior stroke) with residual deficit 4. Alcoholism (\> 2 drinks/day) 5. History of psychiatric illness (any clinical diagnoses requiring therapy) 6. History of drug abuse (any illicit drug use in the past 3 months) 7. Hepatic insufficiency (liver function tests \> 1.5 times the upper limit of normal) 8. Severe pulmonary insufficiency (requiring home oxygen therapy) 9. Renal failure (baseline serum creatinine \> 2.0 mg/dl) 10. Pregnant women 11. Unable to read and thus unable to complete the cognitive testing 12. Score \< 24 on a baseline Mini Mental State examination (MMSE) or greater than or equal to 27 on the baseline Center for Epidemiological Studies Depression (CES-D) Scale -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change | Preoperative to 6 weeks after surgery | To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. |
| Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome | Preoperative to 6 weeks after surgery | To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Transcerebral Activation Gradients of Monocytes | Baseline to 6 hours post cross-clamp removal | Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups |
| Transcerebral Activation Gradient of Platelet-neutrophil Conjugates | Baseline to 6 hours post cross-clamp removal | Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups |
| Change in Cognitive Function From Baseline | 1 year after surgery | To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement |
| Change in Duke Activity Status Index (DASI) | baseline, 6-weeks | The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function. |
| Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS) | baseline, 6-weeks | The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). |
| Change in Center for Epidemiological Studies Depression Scale (CES-D) | baseline, 6-weeks | Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression. |
| Change in Spielberger State Anxiety Inventory (STAI) | baseline, 6-weeks | Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety. |
| Transcerebral Activation Gradients of Platelets | Baseline to 6 hours post cross-clamp removal | Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups |
| Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL) | baseline, 6-weeks | Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities. |
| Change in the Cognitive Difficulties Scale | baseline, 6-weeks | Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty. |
| Change in Perceived Social Support | baseline, 6-weeks | Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support. |
| Change in Social Activity | baseline, 6-weeks | Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity. |
| Change in Study 36-Item Short Form Health Survey (SF-36) | baseline, 6-weeks | The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. |
| Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS) | baseline, 6-weeks | The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. |
| Change in Symptom Limitations | baseline, 6-weeks | Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. |
| Transcerebral Activation Gradients of Neutrophils | Baseline to 6 hours post cross-clamp removal | Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups |
Countries
United States
Participant flow
Recruitment details
550 participants consented; 478 participants were randomized.
Participants by arm
| Arm | Count |
|---|---|
| Lidocaine Lidocaine infusion for 48 hours
Lidocaine: Lidocaine versus placebo infusion for 48 hours | 211 |
| Placebo Normal saline infusion for 48 hours
Placebo: Lidocaine versus placebo infusion for 48 hours | 209 |
| Total | 420 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 3 | 3 |
| Overall Study | Found to Meet Exclusion Criteria | 3 | 4 |
| Overall Study | Lost to Follow-up | 2 | 3 |
| Overall Study | Withdrawal by Subject | 22 | 18 |
Baseline characteristics
| Characteristic | Lidocaine | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 66.9 years STANDARD_DEVIATION 9.1 | 66.5 years STANDARD_DEVIATION 9.5 | 66.7 years STANDARD_DEVIATION 9.3 |
| Region of Enrollment United States | 211 Participants | 209 Participants | 420 Participants |
| Sex: Female, Male Female | 60 Participants | 49 Participants | 109 Participants |
| Sex: Female, Male Male | 151 Participants | 160 Participants | 311 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 6 / 241 | 7 / 237 |
| other Total, other adverse events | 34 / 241 | 34 / 237 |
| serious Total, serious adverse events | 105 / 241 | 103 / 237 |
Outcome results
Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement.
Time frame: Preoperative to 6 weeks after surgery
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change | 0.07 units on a scale | Standard Deviation 0.32 |
| Placebo | Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change | 0.07 units on a scale | Standard Deviation 0.37 |
Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains.
Time frame: Preoperative to 6 weeks after surgery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Lidocaine | Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome | 87 Participants |
| Placebo | Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome | 83 Participants |
Change in Center for Epidemiological Studies Depression Scale (CES-D)
Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression.
Time frame: baseline, 1-year
Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Center for Epidemiological Studies Depression Scale (CES-D) | -1.27 units on a scale | Standard Deviation 7.7 |
| Placebo | Change in Center for Epidemiological Studies Depression Scale (CES-D) | -0.89 units on a scale | Standard Deviation 7.9 |
Change in Center for Epidemiological Studies Depression Scale (CES-D)
Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression.
Time frame: baseline, 6-weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Center for Epidemiological Studies Depression Scale (CES-D) | 0.57 units on a scale | Standard Deviation 7.5 |
| Placebo | Change in Center for Epidemiological Studies Depression Scale (CES-D) | 0.16 units on a scale | Standard Deviation 8.3 |
Change in Cognitive Function From Baseline
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement
Time frame: 1 year after surgery
Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Cognitive Function From Baseline | 0.09 units on a scale | Standard Deviation 0.34 |
| Placebo | Change in Cognitive Function From Baseline | 0.07 units on a scale | Standard Deviation 0.34 |
Change in Duke Activity Status Index (DASI)
The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function.
Time frame: baseline, 1-year
Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Duke Activity Status Index (DASI) | 6.3 units on a scale | Standard Deviation 18.3 |
| Placebo | Change in Duke Activity Status Index (DASI) | 6.96 units on a scale | Standard Deviation 16.9 |
Change in Duke Activity Status Index (DASI)
The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function.
Time frame: baseline, 6-weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Duke Activity Status Index (DASI) | -10.98 units on a scale | Standard Deviation 15.4 |
| Placebo | Change in Duke Activity Status Index (DASI) | -11.67 units on a scale | Standard Deviation 16.8 |
Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient).
Time frame: baseline, 6-weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS) | 0.05 units on a scale | Standard Deviation 0.5 |
| Placebo | Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS) | 0.04 units on a scale | Standard Deviation 0.5 |
Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient).
Time frame: baseline, 1-year
Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS) | 0.05 units on a scale | Standard Deviation 0.7 |
| Placebo | Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS) | 0.07 units on a scale | Standard Deviation 0.6 |
Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function.
Time frame: baseline, 1-year
Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS) | 0.02 units on a scale | Standard Deviation 1.1 |
| Placebo | Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS) | -0.02 units on a scale | Standard Deviation 1.2 |
Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function.
Time frame: baseline, 6-weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS) | 0.04 units on a scale | Standard Deviation 1.1 |
| Placebo | Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS) | -0.01 units on a scale | Standard Deviation 1.3 |
Change in Perceived Social Support
Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support.
Time frame: baseline, 1-year
Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Perceived Social Support | 0.71 units on a scale | Standard Deviation 13.4 |
| Placebo | Change in Perceived Social Support | -1.16 units on a scale | Standard Deviation 12.9 |
Change in Perceived Social Support
Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support.
Time frame: baseline, 6-weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Perceived Social Support | 1.23 units on a scale | Standard Deviation 14 |
| Placebo | Change in Perceived Social Support | -0.49 units on a scale | Standard Deviation 13.9 |
Change in Social Activity
Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity.
Time frame: baseline, 1-year
Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Social Activity | -0.20 units on a scale | Standard Deviation 3.2 |
| Placebo | Change in Social Activity | 0.03 units on a scale | Standard Deviation 3.4 |
Change in Social Activity
Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity.
Time frame: baseline, 6-weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Social Activity | 0.95 units on a scale | Standard Deviation 3.4 |
| Placebo | Change in Social Activity | 1.59 units on a scale | Standard Deviation 3.2 |
Change in Spielberger State Anxiety Inventory (STAI)
Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety.
Time frame: baseline, 6-weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Spielberger State Anxiety Inventory (STAI) | -7.12 units on a scale | Standard Deviation 12.1 |
| Placebo | Change in Spielberger State Anxiety Inventory (STAI) | -6.31 units on a scale | Standard Deviation 11.4 |
Change in Spielberger State Anxiety Inventory (STAI)
Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety.
Time frame: baseline, 1-year
Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Spielberger State Anxiety Inventory (STAI) | -6.70 units on a scale | Standard Deviation 12.7 |
| Placebo | Change in Spielberger State Anxiety Inventory (STAI) | -6.39 units on a scale | Standard Deviation 10.3 |
Change in Study 36-Item Short Form Health Survey (SF-36)
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state.
Time frame: baseline, 6-weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lidocaine | Change in Study 36-Item Short Form Health Survey (SF-36) | 6-Week Change Work activities | 2.71 units on a scale | Standard Deviation 4.9 |
| Lidocaine | Change in Study 36-Item Short Form Health Survey (SF-36) | 6-Week Change General health perception | -0.004 units on a scale | Standard Deviation 1.3 |
| Placebo | Change in Study 36-Item Short Form Health Survey (SF-36) | 6-Week Change Work activities | 3 units on a scale | Standard Deviation 4.3 |
| Placebo | Change in Study 36-Item Short Form Health Survey (SF-36) | 6-Week Change General health perception | -0.03 units on a scale | Standard Deviation 1.2 |
Change in Study 36-Item Short Form Health Survey (SF-36)
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state.
Time frame: baseline, 1-year
Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lidocaine | Change in Study 36-Item Short Form Health Survey (SF-36) | 1 year Change Work Activities | -1.37 units on a scale | Standard Deviation 4.3 |
| Lidocaine | Change in Study 36-Item Short Form Health Survey (SF-36) | 1 year Change General health perception | -0.28 units on a scale | Standard Deviation 1.2 |
| Placebo | Change in Study 36-Item Short Form Health Survey (SF-36) | 1 year Change Work Activities | -1.42 units on a scale | Standard Deviation 4.1 |
| Placebo | Change in Study 36-Item Short Form Health Survey (SF-36) | 1 year Change General health perception | -0.43 units on a scale | Standard Deviation 1.1 |
Change in Symptom Limitations
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations.
Time frame: baseline, 1-year
Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Symptom Limitations | -1.39 units on a scale | Standard Deviation 3.8 |
| Placebo | Change in Symptom Limitations | -1.48 units on a scale | Standard Deviation 3.8 |
Change in Symptom Limitations
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations.
Time frame: baseline, 6-weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in Symptom Limitations | -0.67 units on a scale | Standard Deviation 4 |
| Placebo | Change in Symptom Limitations | -0.8 units on a scale | Standard Deviation 3.9 |
Change in the Cognitive Difficulties Scale
Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty.
Time frame: baseline, 6-weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in the Cognitive Difficulties Scale | -3 units on a scale | Standard Deviation 14.6 |
| Placebo | Change in the Cognitive Difficulties Scale | -3.21 units on a scale | Standard Deviation 15.9 |
Change in the Cognitive Difficulties Scale
Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty.
Time frame: baseline, 1-year
Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in the Cognitive Difficulties Scale | -0.46 units on a scale | Standard Deviation 16.1 |
| Placebo | Change in the Cognitive Difficulties Scale | -1.02 units on a scale | Standard Deviation 17 |
Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)
Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities.
Time frame: baseline, 1-year
Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL) | -0.15 units on a scale | Standard Deviation 2.1 |
| Placebo | Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL) | -0.31 units on a scale | Standard Deviation 2.6 |
Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)
Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities.
Time frame: baseline, 6-weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lidocaine | Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL) | 2.46 units on a scale | Standard Deviation 4.2 |
| Placebo | Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL) | 2.1 units on a scale | Standard Deviation 3.9 |
Transcerebral Activation Gradient of Platelet-neutrophil Conjugates
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups
Time frame: Baseline to 6 hours post cross-clamp removal
Population: Planned substudy, that was analyzed after 202 enrolled subjects.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lidocaine | Transcerebral Activation Gradient of Platelet-neutrophil Conjugates | Baseline | -0.15 Mean linear fluorescence intensity-MLFI | Standard Deviation 9.64 |
| Lidocaine | Transcerebral Activation Gradient of Platelet-neutrophil Conjugates | Cross-clamp removal | 0.02 Mean linear fluorescence intensity-MLFI | Standard Deviation 4.33 |
| Lidocaine | Transcerebral Activation Gradient of Platelet-neutrophil Conjugates | End of Bypass | -0.73 Mean linear fluorescence intensity-MLFI | Standard Deviation 4.99 |
| Lidocaine | Transcerebral Activation Gradient of Platelet-neutrophil Conjugates | 6 hours post cross-clamp removal | -0.10 Mean linear fluorescence intensity-MLFI | Standard Deviation 5.4 |
| Placebo | Transcerebral Activation Gradient of Platelet-neutrophil Conjugates | 6 hours post cross-clamp removal | 0.19 Mean linear fluorescence intensity-MLFI | Standard Deviation 4.73 |
| Placebo | Transcerebral Activation Gradient of Platelet-neutrophil Conjugates | Baseline | -0.43 Mean linear fluorescence intensity-MLFI | Standard Deviation 8.4 |
| Placebo | Transcerebral Activation Gradient of Platelet-neutrophil Conjugates | End of Bypass | -0.40 Mean linear fluorescence intensity-MLFI | Standard Deviation 5.12 |
| Placebo | Transcerebral Activation Gradient of Platelet-neutrophil Conjugates | Cross-clamp removal | -0.73 Mean linear fluorescence intensity-MLFI | Standard Deviation 3.97 |
Transcerebral Activation Gradients of Monocytes
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups
Time frame: Baseline to 6 hours post cross-clamp removal
Population: Planned substudy, that was analyzed after 202 enrolled subjects.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lidocaine | Transcerebral Activation Gradients of Monocytes | Baseline | -4.22 Mean linear fluorescence intensity-MLFI | Standard Deviation 19.1 |
| Lidocaine | Transcerebral Activation Gradients of Monocytes | Cross-clamp removal | -2.46 Mean linear fluorescence intensity-MLFI | Standard Deviation 16.94 |
| Lidocaine | Transcerebral Activation Gradients of Monocytes | End of Bypass | -0.34 Mean linear fluorescence intensity-MLFI | Standard Deviation 19.57 |
| Lidocaine | Transcerebral Activation Gradients of Monocytes | 6 hours post cross-clamp removal | 1.21 Mean linear fluorescence intensity-MLFI | Standard Deviation 15.08 |
| Placebo | Transcerebral Activation Gradients of Monocytes | 6 hours post cross-clamp removal | 0.54 Mean linear fluorescence intensity-MLFI | Standard Deviation 13.69 |
| Placebo | Transcerebral Activation Gradients of Monocytes | Baseline | -0.04 Mean linear fluorescence intensity-MLFI | Standard Deviation 17.78 |
| Placebo | Transcerebral Activation Gradients of Monocytes | End of Bypass | 2.64 Mean linear fluorescence intensity-MLFI | Standard Deviation 15.69 |
| Placebo | Transcerebral Activation Gradients of Monocytes | Cross-clamp removal | 1.83 Mean linear fluorescence intensity-MLFI | Standard Deviation 16.8 |
Transcerebral Activation Gradients of Neutrophils
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups
Time frame: Baseline to 6 hours post cross-clamp removal
Population: Planned substudy, that was analyzed after 202 enrolled subjects
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lidocaine | Transcerebral Activation Gradients of Neutrophils | Baseline | -2.02 Mean linear fluorescence intensity-MLFI | Standard Deviation 8.15 |
| Lidocaine | Transcerebral Activation Gradients of Neutrophils | Cross-clamp removal | 0.56 Mean linear fluorescence intensity-MLFI | Standard Deviation 6.82 |
| Lidocaine | Transcerebral Activation Gradients of Neutrophils | End of Bypass | 0.58 Mean linear fluorescence intensity-MLFI | Standard Deviation 4.54 |
| Lidocaine | Transcerebral Activation Gradients of Neutrophils | 6 hours post cross-clamp removal | 1.04 Mean linear fluorescence intensity-MLFI | Standard Deviation 7.08 |
| Placebo | Transcerebral Activation Gradients of Neutrophils | 6 hours post cross-clamp removal | -0.68 Mean linear fluorescence intensity-MLFI | Standard Deviation 8.61 |
| Placebo | Transcerebral Activation Gradients of Neutrophils | Baseline | -0.08 Mean linear fluorescence intensity-MLFI | Standard Deviation 9.17 |
| Placebo | Transcerebral Activation Gradients of Neutrophils | End of Bypass | 1.19 Mean linear fluorescence intensity-MLFI | Standard Deviation 6.76 |
| Placebo | Transcerebral Activation Gradients of Neutrophils | Cross-clamp removal | 0.17 Mean linear fluorescence intensity-MLFI | Standard Deviation 5.53 |
Transcerebral Activation Gradients of Platelets
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups
Time frame: Baseline to 6 hours post cross-clamp removal
Population: Planned substudy, that was analyzed after 202 enrolled subjects
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lidocaine | Transcerebral Activation Gradients of Platelets | Baseline | -0.03 Mean linear fluorescence intensity-MLFI | Standard Deviation 0.79 |
| Lidocaine | Transcerebral Activation Gradients of Platelets | Cross-clamp removal | 0.03 Mean linear fluorescence intensity-MLFI | Standard Deviation 1.21 |
| Lidocaine | Transcerebral Activation Gradients of Platelets | End of Bypass | 0.33 Mean linear fluorescence intensity-MLFI | Standard Deviation 3.25 |
| Lidocaine | Transcerebral Activation Gradients of Platelets | 6 hours post cross-clamp removal | 0.37 Mean linear fluorescence intensity-MLFI | Standard Deviation 2.65 |
| Placebo | Transcerebral Activation Gradients of Platelets | 6 hours post cross-clamp removal | 0.27 Mean linear fluorescence intensity-MLFI | Standard Deviation 1.07 |
| Placebo | Transcerebral Activation Gradients of Platelets | Baseline | 0.35 Mean linear fluorescence intensity-MLFI | Standard Deviation 1.91 |
| Placebo | Transcerebral Activation Gradients of Platelets | End of Bypass | 0.05 Mean linear fluorescence intensity-MLFI | Standard Deviation 2.65 |
| Placebo | Transcerebral Activation Gradients of Platelets | Cross-clamp removal | 0.43 Mean linear fluorescence intensity-MLFI | Standard Deviation 1.44 |